This is a demo store. No orders will be fulfilled.

Global Vaccine Growth Opportunities

Global Vaccine Growth Opportunities

Capability Expansion in Nucleic Acid-based Vaccines is Accelerating the Disruption in Vaccines Globally

RELEASE DATE
18-Apr-2022
REGION
North America
Research Code: PCCF-01-00-00-00
SKU: HC03531-NA-MT_26454
$4,950.00
In stock
SKU
HC03531-NA-MT_26454
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Frost & Sullivan provides an outlook for the global vaccine industry for 2022 and beyond, including emerging trends and growth opportunities. Innovation, which remains mainstream in vaccine development, is augmenting investments by emerging vaccine developers in designing novel technology platforms, especially for nucleic acid-based vaccines. Spurred by the ongoing pandemic, vaccine developers have accelerated the pace of transformation, and the concepts of manufacturing decentralization, digitization of supply-chain, and increased outsourcing have taken center stage. Moreover, companies entering into public-private-partnerships to capitalize on the current situation are likely to establish synergistic relationships at all levels.

The new vision in 2022 is focused on government authorities having several shifts in vaccine development programs and reaching “zero-dose” children to attain vaccination equity in emerging economies. The tailored and targeted approach used by logistics companies for individual vaccines is providing catalytic support to vendors in the vaccine industry. The adoption of innovative technologies and supply-chain resilience by manufacturers to improve their strategic position in the global vaccine market, while ensuring the accessibility of vaccines remains outcome-based in countries with unmet needs, is a prominently emerging business model. The rising focus on prophylactic management of COVID-19 in 2021-2022 is anticipated to shift toward novel delivery modes of traditional vaccines and on highly prevalent disease areas, such as RSV, HIV, and cancer. Technology transfer is crucial for outsourcing to CDMOs, and the shift toward the development of patient-centric models for vaccine delivery is paramount.


Research Highlights

  • Traditional and COVID-19 vaccine market size, including key segments from 2022 to 2027
  • Dynamics around COVID-19 vaccination and the path to endemicity
  • Role of advancements, such as decentralization, technologies, and new modalities, in driving the vaccine value-chain transformation
  • The current and future R&D and investment outlook, and its evolution
  • Strategic time-defined growth opportunities for ecosystem participants to focus on in the near future

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

Top Three Strategic Imperatives in the Global Vaccines Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Vaccine Landscape—Key Takeaways

Growth Opportunity Matrix

Scope of Analysis

Vaccines—Introduction and Segmentation

Definitions—By Production System

Definitions—By Technology Type

Definitions—By Technology Type (continued)

Growth Drivers for Vaccines Market

Growth Restraints for Vaccines Market

Vaccine Coverage Rate

Areas of Unmet Vaccine Needs

Government Initiatives in Vaccines Industry, 2021

Vaccine Developers Landscape

Pipeline Snapshot, COVID-19 Vaccines

Pipeline Snapshot, Vaccines, 2021

Vaccines Supply Chain—Key Stakeholders

Vaccines Value Chain—The Expanding Role of Different Stakeholders

Vaccines Distribution Framework

Vaccines Distribution Scenario

Evolving Vaccine Delivery Model—Private Sector Fortifying Distribution

Increasing Role of Digital Technology in Vaccines Supply Chain

Key Partnerships and Collaborations, Traditional Vaccines, 2020–2022

Key Partnerships and Collaborations, COVID-19 Vaccines, 2020–2022

Key Partnerships and Collaborations, COVID-19 Vaccines, 2020–2022 (continued)

Key Manufacturing Partnerships With Bio-CDMOs for Approved COVID-19 Vaccines—US

Key Manufacturing Partnerships With Bio-CDMOs for Approved COVID-19 Vaccines—Europe

Key Strategies in the Vaccine Industry

Technological Advancements in Vaccines Industry

Key Growth Metrics for Traditional Vaccines

Research Methodology

Forecast Assumptions

Revenue Forecast

Revenue Forecast Analysis

Revenue Forecast by Technology Type

Percent Revenue Forecast by Technology Type

Revenue by Production System

Percent Revenue by Region

Competitive Environment

Market Share Analysis

Key Growth Metrics

Research Methodology

Forecast Assumptions

Revenue Forecast

Revenue Forecast Analysis

Revenue by Technology Type

Revenue by Production System

Percent Revenue by Region

Competitive Environment

Market Share Analysis

Companies to Watch From 2022–2027

Companies to Watch From 2022–2027 (continued)

Growth Opportunity 1—Building Capabilities for the Development of Nucleic Acid-based Vaccines for Cancer and HIV

Growth Opportunity 1—Building Capabilities for the Development of Nucleic Acid-based Vaccines for Cancer and HIV (continued)

Promising Key Nucleic Acid-based Vaccines in the Pipeline

Growth Opportunity 2—Pediatric Combination Vaccines for Highly Prevalent Infectious Diseases

Growth Opportunity 2—Pediatric Combination Vaccines for Highly Prevalent Infectious Diseases (continued)

Mitigation Measures for Combination Vaccines

Growth Opportunity 3—Tech Transfer in Emerging Economies to Boost the Production Efficiency and Pace

Growth Opportunity 3—Tech Transfer in Emerging Economies to Boost the Production Efficiency and Pace (continued)

Growth Opportunity 4—Developing Countries Entering Into Licensing and Joint Ventures to Build Domestic Capabilities

Growth Opportunity 4—Developing Countries Entering into Licensing and Joint Ventures to Build Domestic Capabilities (continued)

Growth Opportunity 5—Exploring New Disease Areas to Meet the Growing Need for Immunization

Growth Opportunity 5—Exploring New Disease Areas to Meet the Growing Need for Immunization (continued)

Growth Opportunity 5—Exploring New Disease Areas to Meet the Growing Need for Immunization (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

Legal Disclaimer

Related Research
Frost & Sullivan provides an outlook for the global vaccine industry for 2022 and beyond, including emerging trends and growth opportunities. Innovation, which remains mainstream in vaccine development, is augmenting investments by emerging vaccine developers in designing novel technology platforms, especially for nucleic acid-based vaccines. Spurred by the ongoing pandemic, vaccine developers have accelerated the pace of transformation, and the concepts of manufacturing decentralization, digitization of supply-chain, and increased outsourcing have taken center stage. Moreover, companies entering into public-private-partnerships to capitalize on the current situation are likely to establish synergistic relationships at all levels. The new vision in 2022 is focused on government authorities having several shifts in vaccine development programs and reaching “zero-dose” children to attain vaccination equity in emerging economies. The tailored and targeted approach used by logistics companies for individual vaccines is providing catalytic support to vendors in the vaccine industry. The adoption of innovative technologies and supply-chain resilience by manufacturers to improve their strategic position in the global vaccine market, while ensuring the accessibility of vaccines remains outcome-based in countries with unmet needs, is a prominently emerging business model. The rising focus on prophylactic management of COVID-19 in 2021-2022 is anticipated to shift toward novel delivery modes of traditional vaccines and on highly prevalent disease areas, such as RSV, HIV, and cancer. Technology transfer is crucial for outsourcing to CDMOs, and the shift toward the development of patient-centric models for vaccine delivery is paramount.--BEGIN PROMO--

Research Highlights

  • Traditional and COVID-19 vaccine market size, including key segments from 2022 to 2027
  • Dynamics around COVID-19 vaccination and the path to endemicity
  • Role of advancements, such as decentralization, technologies, and new modalities, in driving the vaccine value-chain transformation
  • The current and future R&D and investment outlook, and its evolution
  • Strategic time-defined growth opportunities for ecosystem participants to focus on in the near future
More Information
Author Mrinal Kerhalkar
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number PCCF-01-00-00-00